{"id":"W4281953617","doi":"10.1200/jco.2022.40.16_suppl.7538","title":"Acalabrutinib versus rituximab plus idelalisib or bendamustine in relapsed/refractory chronic lymphocytic leukemia: ASCEND results at 4 years of follow-up.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Saint John Regional Hospital; University of New Brunswick","funders":"","keywords":"Bendamustine; Medicine; Idelalisib; Internal medicine; Chronic lymphocytic leukemia; Tolerability; Gastroenterology; Rituximab; Refractory (planetary science); Toxicity; Progression-free survival; Oncology; Ibrutinib; Leukemia; Overall survival; Adverse effect; Lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.01024671,0.0003144891,0.003231877,0.0005977985,0.0001130453,0.000009403796,0.0008278886,0.0007697922,0.001546956],"category_scores_gemma":[0.02546752,0.000265312,0.000906102,0.0009221803,0.0006725843,0.0001358197,0.0009564746,0.003590366,0.00008292671],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.2193998,"about_ca_system_score_gemma":0.2130824,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008884569,"about_ca_topic_score_gemma":0.0008375262,"domain_scores_codex":[0.9891681,0.001452108,0.005885136,0.0006102879,0.002008756,0.0008756334],"domain_scores_gemma":[0.981927,0.01277523,0.00327755,0.0007915318,0.0005092825,0.0007194522],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7412454,0.003097451,0.000845383,0.0004891012,0.001665656,0.03858717,0.00134142,0.01099321,0.0008309819,0.0001415654,0.08878946,0.1119732],"study_design_scores_gemma":[0.6644254,0.06365177,0.006101202,0.0003523809,0.0006617998,0.003486056,0.0006904094,0.01349842,0.0001817217,0.00006350305,0.2465452,0.0003421322],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9881307,0.002011349,0.000005308086,0.001240614,0.004628369,0.0005158363,0.00005406672,0.00002333077,0.003390454],"genre_scores_gemma":[0.9908279,0.001605281,0.0005908842,0.0005491399,0.001434406,0.00001981152,0.00002967511,0.00006993071,0.004872955],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1577557,"threshold_uncertainty_score":0.9999799,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1575472935405038,"score_gpt":0.4610444198356924,"score_spread":0.3034971262951887,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}